FDA Announces OMB Approval for In Vivo Radiopharmaceutical Regulations

Summary

The Food and Drug Administration (FDA) is announcing that a collection of information entitled 'Regulations for In Vivo Radiopharmaceuticals Used for Diagnosis and Monitoring' has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995, which will help streamline the regulatory process for the use of in vivo radiopharmaceuticals in medical diagnosis and monitoring.